APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroprotective Products

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neuroprotective Products Market Outlook and Growth Opportunities 2026

22 December 2025209 pages

Choose your research edition.

Industry ResearchNeuroprotective Products Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroprotective Products Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Neuroprotective Products Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroprotective Products Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroprotective Products Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Neuroprotective Products market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neuroprotective Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroprotective Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroprotective Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neuroprotective Products market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neuroprotective Products market include Teva Pharmaceutical Industries Ltd, Novartis, Merck KGaA, Pfizer Inc, GlaxoSmithKline plc., Biogen, AstraZeneca, Sunovion Pharmaceuticals Inc and NeuroVive Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuroprotective Products market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroprotective Products and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroprotective Products sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuroprotective Products market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuroprotective Products Segment by Company

Teva Pharmaceutical Industries Ltd

Novartis

Merck KGaA

Pfizer Inc

GlaxoSmithKline plc.

Biogen

AstraZeneca

Sunovion Pharmaceuticals Inc

NeuroVive Pharmaceutical

Neuren Pharmaceuticals

Hikma Pharmaceuticals PLC

Genervon Biopharmaceuticals

Ceregene

Bionure

Bioniz Theraputics.

BHR Pharma

Allon therapeutics

Neuroprotective Products Segment by Type

Cholinesterase inhibitors

NMDA receptor antagonists

Others

Neuroprotective Products Segment by Application

Alzheimer's disease

Multiple sclerosis

Others

Neuroprotective Products Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neuroprotective Products status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neuroprotective Products market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuroprotective Products significant trends, drivers, influence factors in global and regions.

6. To analyze Neuroprotective Products competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroprotective Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroprotective Products and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroprotective Products.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuroprotective Products market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuroprotective Products industry.

Chapter 3: Detailed analysis of Neuroprotective Products manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neuroprotective Products in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neuroprotective Products in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuroprotective Products Industry Trends Table 2. Neuroprotective Products Industry Drivers Table 3. Neuroprotective Products Industry Opportunities and Challenges Table 4. Neuroprotective Products Industry Restraints Table 5. Global Neuroprotective Products Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuroprotective Products Revenue Share by Company (2021-2026) Table 7. Global Neuroprotective Products Sales Volume by Company (tons) & (2021-2026) Table 8. Global Neuroprotective Products Sales Volume Share by Company (2021-2026) Table 9. Global Neuroprotective Products Average Price (US$/ton) of Company (2021-2026) Table 10. Global Neuroprotective Products Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neuroprotective Products Key Company Manufacturing Base & Headquarters Table 12. Global Neuroprotective Products Company, Product Type & Application Table 13. Global Neuroprotective Products Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuroprotective Products by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Cholinesterase inhibitors Table 18. Significant Companies of NMDA receptor antagonists Table 19. Significant Companies of Others Table 20. Global Neuroprotective Products Sales Volume by Type 2021 VS 2025 VS 2032 (tons) Table 21. Global Neuroprotective Products Sales Volume by Type (2021-2026) & (tons) Table 22. Global Neuroprotective Products Sales Volume by Type (2027-2032) & (tons) Table 23. Global Neuroprotective Products Sales Volume Share by Type (2021-2026) Table 24. Global Neuroprotective Products Sales Volume Share by Type (2027-2032) Table 25. Global Neuroprotective Products Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Neuroprotective Products Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Neuroprotective Products Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Neuroprotective Products Sales Value Share by Type (2021-2026) Table 29. Global Neuroprotective Products Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Alzheimer's disease Table 31. Significant Companies of Multiple sclerosis Table 32. Significant Companies of Others Table 33. Global Neuroprotective Products Sales Volume by Application 2021 VS 2025 VS 2032 (tons) Table 34. Global Neuroprotective Products Sales Volume by Application (2021-2026) & (tons) Table 35. Global Neuroprotective Products Sales Volume by Application (2027-2032) & (tons) Table 36. Global Neuroprotective Products Sales Volume Share by Application (2021-2026) Table 37. Global Neuroprotective Products Sales Volume Share by Application (2027-2032) Table 38. Global Neuroprotective Products Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Neuroprotective Products Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Neuroprotective Products Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Neuroprotective Products Sales Value Share by Application (2021-2026) Table 42. Global Neuroprotective Products Sales Value Share by Application (2027-2032) Table 43. Global Neuroprotective Products Sales by Region: 2021 VS 2025 VS 2032 (tons) Table 44. Global Neuroprotective Products Sales by Region (2021-2026) & (tons) Table 45. Global Neuroprotective Products Sales Market Share by Region (2021-2026) Table 46. Global Neuroprotective Products Sales by Region (2027-2032) & (tons) Table 47. Global Neuroprotective Products Sales Market Share by Region (2027-2032) Table 48. Global Neuroprotective Products Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Neuroprotective Products Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Neuroprotective Products Sales Value Share by Region (2021-2026) Table 51. Global Neuroprotective Products Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Neuroprotective Products Sales Value Share by Region (2027-2032) Table 53. Global Neuroprotective Products Market Average Price (US$/ton) by Region (2021-2026) Table 54. Global Neuroprotective Products Market Average Price (US$/ton) by Region (2027-2032) Table 55. Global Neuroprotective Products Sales by Country: 2021 VS 2025 VS 2032 (tons) Table 56. Global Neuroprotective Products Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Neuroprotective Products Sales by Country (2021-2026) & (tons) Table 58. Global Neuroprotective Products Sales Market Share by Country (2021-2026) Table 59. Global Neuroprotective Products Sales by Country (2027-2032) & (tons) Table 60. Global Neuroprotective Products Sales Market Share by Country (2027-2032) Table 61. Global Neuroprotective Products Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Neuroprotective Products Sales Value Market Share by Country (2021-2026) Table 63. Global Neuroprotective Products Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Neuroprotective Products Sales Value Market Share by Country (2027-2032) Table 65. Teva Pharmaceutical Industries Ltd Company Information Table 66. Teva Pharmaceutical Industries Ltd Business Overview Table 67. Teva Pharmaceutical Industries Ltd Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 68. Teva Pharmaceutical Industries Ltd Neuroprotective Products Product Portfolio Table 69. Teva Pharmaceutical Industries Ltd Recent Development Table 70. Novartis Company Information Table 71. Novartis Business Overview Table 72. Novartis Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 73. Novartis Neuroprotective Products Product Portfolio Table 74. Novartis Recent Development Table 75. Merck KGaA Company Information Table 76. Merck KGaA Business Overview Table 77. Merck KGaA Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 78. Merck KGaA Neuroprotective Products Product Portfolio Table 79. Merck KGaA Recent Development Table 80. Pfizer Inc Company Information Table 81. Pfizer Inc Business Overview Table 82. Pfizer Inc Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 83. Pfizer Inc Neuroprotective Products Product Portfolio Table 84. Pfizer Inc Recent Development Table 85. GlaxoSmithKline plc. Company Information Table 86. GlaxoSmithKline plc. Business Overview Table 87. GlaxoSmithKline plc. Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 88. GlaxoSmithKline plc. Neuroprotective Products Product Portfolio Table 89. GlaxoSmithKline plc. Recent Development Table 90. Biogen Company Information Table 91. Biogen Business Overview Table 92. Biogen Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 93. Biogen Neuroprotective Products Product Portfolio Table 94. Biogen Recent Development Table 95. AstraZeneca Company Information Table 96. AstraZeneca Business Overview Table 97. AstraZeneca Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 98. AstraZeneca Neuroprotective Products Product Portfolio Table 99. AstraZeneca Recent Development Table 100. Sunovion Pharmaceuticals Inc Company Information Table 101. Sunovion Pharmaceuticals Inc Business Overview Table 102. Sunovion Pharmaceuticals Inc Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 103. Sunovion Pharmaceuticals Inc Neuroprotective Products Product Portfolio Table 104. Sunovion Pharmaceuticals Inc Recent Development Table 105. NeuroVive Pharmaceutical Company Information Table 106. NeuroVive Pharmaceutical Business Overview Table 107. NeuroVive Pharmaceutical Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 108. NeuroVive Pharmaceutical Neuroprotective Products Product Portfolio Table 109. NeuroVive Pharmaceutical Recent Development Table 110. Neuren Pharmaceuticals Company Information Table 111. Neuren Pharmaceuticals Business Overview Table 112. Neuren Pharmaceuticals Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 113. Neuren Pharmaceuticals Neuroprotective Products Product Portfolio Table 114. Neuren Pharmaceuticals Recent Development Table 115. Hikma Pharmaceuticals PLC Company Information Table 116. Hikma Pharmaceuticals PLC Business Overview Table 117. Hikma Pharmaceuticals PLC Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 118. Hikma Pharmaceuticals PLC Neuroprotective Products Product Portfolio Table 119. Hikma Pharmaceuticals PLC Recent Development Table 120. Genervon Biopharmaceuticals Company Information Table 121. Genervon Biopharmaceuticals Business Overview Table 122. Genervon Biopharmaceuticals Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 123. Genervon Biopharmaceuticals Neuroprotective Products Product Portfolio Table 124. Genervon Biopharmaceuticals Recent Development Table 125. Ceregene Company Information Table 126. Ceregene Business Overview Table 127. Ceregene Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 128. Ceregene Neuroprotective Products Product Portfolio Table 129. Ceregene Recent Development Table 130. Bionure Company Information Table 131. Bionure Business Overview Table 132. Bionure Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 133. Bionure Neuroprotective Products Product Portfolio Table 134. Bionure Recent Development Table 135. Bioniz Theraputics. Company Information Table 136. Bioniz Theraputics. Business Overview Table 137. Bioniz Theraputics. Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 138. Bioniz Theraputics. Neuroprotective Products Product Portfolio Table 139. Bioniz Theraputics. Recent Development Table 140. BHR Pharma Company Information Table 141. BHR Pharma Business Overview Table 142. BHR Pharma Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 143. BHR Pharma Neuroprotective Products Product Portfolio Table 144. BHR Pharma Recent Development Table 145. Allon therapeutics Company Information Table 146. Allon therapeutics Business Overview Table 147. Allon therapeutics Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 148. Allon therapeutics Neuroprotective Products Product Portfolio Table 149. Allon therapeutics Recent Development Table 150. Key Raw Materials Table 151. Raw Materials Key Suppliers Table 152. Neuroprotective Products Distributors List Table 153. Neuroprotective Products Customers List Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Neuroprotective Products Product Image Figure 2. Global Neuroprotective Products Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroprotective Products Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neuroprotective Products Sales (2021-2032) & (tons) Figure 5. Global Neuroprotective Products Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Neuroprotective Products Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Cholinesterase inhibitors Image Figure 10. NMDA receptor antagonists Image Figure 11. Others Image Figure 12. Global Neuroprotective Products Sales Volume by Type (2021 VS 2025 VS 2032) & (tons) Figure 13. Global Neuroprotective Products Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Neuroprotective Products Sales Volume Share by Type (2021-2032) Figure 15. Global Neuroprotective Products Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Neuroprotective Products Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Neuroprotective Products Sales Value Share by Type (2021-2032) Figure 18. Alzheimer's disease Image Figure 19. Multiple sclerosis Image Figure 20. Others Image Figure 21. Global Neuroprotective Products Sales Volume by Application (2021 VS 2025 VS 2032) & (tons) Figure 22. Global Neuroprotective Products Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Neuroprotective Products Sales Volume Share by Application (2021-2032) Figure 24. Global Neuroprotective Products Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Neuroprotective Products Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Neuroprotective Products Sales Value Share by Application (2021-2032) Figure 27. Global Neuroprotective Products Sales by Region: 2021 VS 2025 VS 2032 (tons) Figure 28. Global Neuroprotective Products Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Neuroprotective Products Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Neuroprotective Products Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Neuroprotective Products Sales Value (2021-2032) & (US$ Million) Figure 32. North America Neuroprotective Products Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Neuroprotective Products Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Neuroprotective Products Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Neuroprotective Products Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Neuroprotective Products Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Neuroprotective Products Sales Value (2021-2032) & (US$ Million) Figure 38. South America Neuroprotective Products Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Neuroprotective Products Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Neuroprotective Products Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Neuroprotective Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Neuroprotective Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Neuroprotective Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Neuroprotective Products Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Neuroprotective Products Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Cholinesterase inhibitors
  • NMDA receptor antagonists
  • Others
Applications
  • Alzheimer's disease
  • Multiple sclerosis
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Novartis
  • Merck KGaA
  • Pfizer Inc
  • GlaxoSmithKline plc.
  • Biogen
  • AstraZeneca
  • Sunovion Pharmaceuticals Inc
  • NeuroVive Pharmaceutical
  • Neuren Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Genervon Biopharmaceuticals
  • Ceregene
  • Bionure
  • Bioniz Theraputics.
  • BHR Pharma
  • Allon therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuroprotective Products Sales Value (2021-2032)
  4. 1.2.2 Global Neuroprotective Products Sales Volume (2021-2032)
  5. 1.2.3 Global Neuroprotective Products Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neuroprotective Products Market Dynamics
  1. 2.1 Neuroprotective Products Industry Trends
  2. 2.2 Neuroprotective Products Industry Drivers
  3. 2.3 Neuroprotective Products Industry Opportunities and Challenges
  4. 2.4 Neuroprotective Products Industry Restraints
3 Neuroprotective Products Market by Company
  1. 3.1 Global Neuroprotective Products Company Revenue Ranking in 2025
  2. 3.2 Global Neuroprotective Products Revenue by Company (2021-2026)
  3. 3.3 Global Neuroprotective Products Sales Volume by Company (2021-2026)
  4. 3.4 Global Neuroprotective Products Average Price by Company (2021-2026)
  5. 3.5 Global Neuroprotective Products Company Ranking (2024-2026)
  6. 3.6 Global Neuroprotective Products Company Manufacturing Base and Headquarters
  7. 3.7 Global Neuroprotective Products Company Product Type and Application
  8. 3.8 Global Neuroprotective Products Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neuroprotective Products Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neuroprotective Products Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neuroprotective Products Market by Type
  1. 4.1 Neuroprotective Products Type Introduction
  2. 4.1.1 Cholinesterase inhibitors
  3. 4.1.2 NMDA receptor antagonists
  4. 4.1.3 Others
  5. 4.2 Global Neuroprotective Products Sales Volume by Type
  6. 4.2.1 Global Neuroprotective Products Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neuroprotective Products Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Neuroprotective Products Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Neuroprotective Products Sales Value by Type
  10. 4.3.1 Global Neuroprotective Products Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Neuroprotective Products Sales Value by Type (2021-2032)
  12. 4.3.3 Global Neuroprotective Products Sales Value Share by Type (2021-2032)
5 Neuroprotective Products Market by Application
  1. 5.1 Neuroprotective Products Application Introduction
  2. 5.1.1 Alzheimer's disease
  3. 5.1.2 Multiple sclerosis
  4. 5.1.3 Others
  5. 5.2 Global Neuroprotective Products Sales Volume by Application
  6. 5.2.1 Global Neuroprotective Products Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuroprotective Products Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Neuroprotective Products Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Neuroprotective Products Sales Value by Application
  10. 5.3.1 Global Neuroprotective Products Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Neuroprotective Products Sales Value by Application (2021-2032)
  12. 5.3.3 Global Neuroprotective Products Sales Value Share by Application (2021-2032)
6 Neuroprotective Products Regional Sales and Value Analysis
  1. 6.1 Global Neuroprotective Products Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuroprotective Products Sales by Region (2021-2032)
  3. 6.2.1 Global Neuroprotective Products Sales by Region: 2021-2026
  4. 6.2.2 Global Neuroprotective Products Sales by Region (2027-2032)
  5. 6.3 Global Neuroprotective Products Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neuroprotective Products Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neuroprotective Products Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neuroprotective Products Sales Value by Region (2027-2032)
  9. 6.5 Global Neuroprotective Products Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neuroprotective Products Sales Value (2021-2032)
  12. 6.6.2 North America Neuroprotective Products Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neuroprotective Products Sales Value (2021-2032)
  15. 6.7.2 Europe Neuroprotective Products Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neuroprotective Products Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neuroprotective Products Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neuroprotective Products Sales Value (2021-2032)
  21. 6.9.2 South America Neuroprotective Products Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neuroprotective Products Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neuroprotective Products Sales Value Share by Country, 2025 VS 2032
7 Neuroprotective Products Country-level Sales and Value Analysis
  1. 7.1 Global Neuroprotective Products Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuroprotective Products Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neuroprotective Products Sales by Country (2021-2032)
  4. 7.3.1 Global Neuroprotective Products Sales by Country (2021-2026)
  5. 7.3.2 Global Neuroprotective Products Sales by Country (2027-2032)
  6. 7.4 Global Neuroprotective Products Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neuroprotective Products Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neuroprotective Products Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neuroprotective Products Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neuroprotective Products Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neuroprotective Products Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neuroprotective Products Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neuroprotective Products Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neuroprotective Products Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neuroprotective Products Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neuroprotective Products Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neuroprotective Products Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neuroprotective Products Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neuroprotective Products Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neuroprotective Products Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neuroprotective Products Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neuroprotective Products Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neuroprotective Products Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neuroprotective Products Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neuroprotective Products Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neuroprotective Products Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neuroprotective Products Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neuroprotective Products Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neuroprotective Products Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neuroprotective Products Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neuroprotective Products Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neuroprotective Products Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neuroprotective Products Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neuroprotective Products Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neuroprotective Products Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neuroprotective Products Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neuroprotective Products Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neuroprotective Products Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd
  2. 8.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd Neuroprotective Products Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Neuroprotective Products Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck KGaA
  14. 8.3.1 Merck KGaA Company Information
  15. 8.3.2 Merck KGaA Business Overview
  16. 8.3.3 Merck KGaA Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck KGaA Neuroprotective Products Product Portfolio
  18. 8.3.5 Merck KGaA Recent Developments
  19. 8.4 Pfizer Inc
  20. 8.4.1 Pfizer Inc Company Information
  21. 8.4.2 Pfizer Inc Business Overview
  22. 8.4.3 Pfizer Inc Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc Neuroprotective Products Product Portfolio
  24. 8.4.5 Pfizer Inc Recent Developments
  25. 8.5 GlaxoSmithKline plc.
  26. 8.5.1 GlaxoSmithKline plc. Company Information
  27. 8.5.2 GlaxoSmithKline plc. Business Overview
  28. 8.5.3 GlaxoSmithKline plc. Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline plc. Neuroprotective Products Product Portfolio
  30. 8.5.5 GlaxoSmithKline plc. Recent Developments
  31. 8.6 Biogen
  32. 8.6.1 Biogen Company Information
  33. 8.6.2 Biogen Business Overview
  34. 8.6.3 Biogen Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Biogen Neuroprotective Products Product Portfolio
  36. 8.6.5 Biogen Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Neuroprotective Products Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Sunovion Pharmaceuticals Inc
  44. 8.8.1 Sunovion Pharmaceuticals Inc Company Information
  45. 8.8.2 Sunovion Pharmaceuticals Inc Business Overview
  46. 8.8.3 Sunovion Pharmaceuticals Inc Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sunovion Pharmaceuticals Inc Neuroprotective Products Product Portfolio
  48. 8.8.5 Sunovion Pharmaceuticals Inc Recent Developments
  49. 8.9 NeuroVive Pharmaceutical
  50. 8.9.1 NeuroVive Pharmaceutical Company Information
  51. 8.9.2 NeuroVive Pharmaceutical Business Overview
  52. 8.9.3 NeuroVive Pharmaceutical Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 NeuroVive Pharmaceutical Neuroprotective Products Product Portfolio
  54. 8.9.5 NeuroVive Pharmaceutical Recent Developments
  55. 8.10 Neuren Pharmaceuticals
  56. 8.10.1 Neuren Pharmaceuticals Company Information
  57. 8.10.2 Neuren Pharmaceuticals Business Overview
  58. 8.10.3 Neuren Pharmaceuticals Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Neuren Pharmaceuticals Neuroprotective Products Product Portfolio
  60. 8.10.5 Neuren Pharmaceuticals Recent Developments
  61. 8.11 Hikma Pharmaceuticals PLC
  62. 8.11.1 Hikma Pharmaceuticals PLC Company Information
  63. 8.11.2 Hikma Pharmaceuticals PLC Business Overview
  64. 8.11.3 Hikma Pharmaceuticals PLC Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Hikma Pharmaceuticals PLC Neuroprotective Products Product Portfolio
  66. 8.11.5 Hikma Pharmaceuticals PLC Recent Developments
  67. 8.12 Genervon Biopharmaceuticals
  68. 8.12.1 Genervon Biopharmaceuticals Company Information
  69. 8.12.2 Genervon Biopharmaceuticals Business Overview
  70. 8.12.3 Genervon Biopharmaceuticals Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Genervon Biopharmaceuticals Neuroprotective Products Product Portfolio
  72. 8.12.5 Genervon Biopharmaceuticals Recent Developments
  73. 8.13 Ceregene
  74. 8.13.1 Ceregene Company Information
  75. 8.13.2 Ceregene Business Overview
  76. 8.13.3 Ceregene Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Ceregene Neuroprotective Products Product Portfolio
  78. 8.13.5 Ceregene Recent Developments
  79. 8.14 Bionure
  80. 8.14.1 Bionure Company Information
  81. 8.14.2 Bionure Business Overview
  82. 8.14.3 Bionure Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Bionure Neuroprotective Products Product Portfolio
  84. 8.14.5 Bionure Recent Developments
  85. 8.15 Bioniz Theraputics.
  86. 8.15.1 Bioniz Theraputics. Company Information
  87. 8.15.2 Bioniz Theraputics. Business Overview
  88. 8.15.3 Bioniz Theraputics. Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Bioniz Theraputics. Neuroprotective Products Product Portfolio
  90. 8.15.5 Bioniz Theraputics. Recent Developments
  91. 8.16 BHR Pharma
  92. 8.16.1 BHR Pharma Company Information
  93. 8.16.2 BHR Pharma Business Overview
  94. 8.16.3 BHR Pharma Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 BHR Pharma Neuroprotective Products Product Portfolio
  96. 8.16.5 BHR Pharma Recent Developments
  97. 8.17 Allon therapeutics
  98. 8.17.1 Allon therapeutics Company Information
  99. 8.17.2 Allon therapeutics Business Overview
  100. 8.17.3 Allon therapeutics Neuroprotective Products Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Allon therapeutics Neuroprotective Products Product Portfolio
  102. 8.17.5 Allon therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuroprotective Products Value Chain Analysis
  2. 9.1.1 Neuroprotective Products Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuroprotective Products Sales Mode & Process
  6. 9.2 Neuroprotective Products Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuroprotective Products Distributors
  9. 9.2.3 Neuroprotective Products Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst